

July 31, 2025

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

Symbol: LALPATHLAB

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

Scrip Code: 539524

**Sub: Earnings Presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2025**

Dear Sir/Madam,

Please find attached a copy of Company's Q1 FY26 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2025, as approved by the Board of Directors in their meeting held on July 31, 2025.

We request you to please take the same on record.

Thanking You,  
Yours Faithfully,

**For Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**

*Encl.: As above*

# Q1 FY26 Results Presentation



*Dr Lal PathLabs*

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward-looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation, nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

## Disclaimer

# Table of Contents

<b>4</b>	<b>DLPL - At a Glance</b>
<b>5</b>	<b>Q1 FY26 Performance Overview</b>
<b>6</b>	<b>Financials</b>
<b>7</b>	<b>Key Performance Highlights</b>
<b>11</b>	<b>Management Commentary</b>
<b>12</b>	<b>Corporate Overview</b>
<b>36</b>	<b>Shareholding</b>
<b>38</b>	<b>Contact Us</b>

# Dr. Lal PathLabs – At a Glance



75+ years of experience in  
the field of diagnostics



India's Leading & Trusted  
Diagnostics Company



131 Mn patients serviced in  
last 5 years



40 NABL accredited Labs;  
2 CAP accredited Labs

## 6,607

Patient Service Centers (PSC's)

## 5,012

Pathology & Radiology tests;  
Comprehensive Test menu

## 298

Labs; Geographically spread-out  
network

### 10.5%

FY25 Revenue  
Growth

### 48%

ROCE  
Excl. Cash &  
Investments

### 240%

Dividend for  
FY24-25


Credit  
Rating# :  
AA  
Stable

As on March 31, 2025

\*Largest on the basis of revenue

# Issued by Care Ratings Ltd.

# Q1 FY26 Performance Overview



Particulars (Rs. Cr.)	Q1 FY26	Q1 FY25	Gr %	FY25
<b>Revenue</b>	<b>670</b>	<b>602</b>	<b>11.3%</b>	<b>2,461</b>
Material consumed	129	119		481
Employee benefit Expenses	132	117		482
Fees to collection centres	92	84		342
Other Expenses	124	112		460
<b>EBITDA</b>	<b>192</b>	<b>170</b>	<b>13.1%</b>	<b>696</b>
<i>Margins</i>	28.7%	28.2%		28.3%
<i>Other Income</i>	28	21		93
Depreciation Cost	35	35		142
Finance Cost	5	6		22
<b>PBT</b>	<b>181</b>	<b>150</b>	<b>20.8%</b>	<b>625</b>
<i>Margins</i>	27.0%	24.9%		25.4%
<b>PAT</b>	<b>134</b>	<b>108</b>	<b>24.3%</b>	<b>492</b>
<i>Margins</i>	20.0%	17.9%		20.0%
<b>EPS (Basic)</b>	<b>15.9</b>	<b>12.8</b>	<b>24.4%</b>	<b>58.5</b>



## Key performance highlights


- **Revenue reached Rs. 670 crore in Q1 FY26, marking a Y-o-Y increase of 11.3%**
  - Mainly sample volume driven (+10.7% Y-o-Y); Led by calibrated network expansion in our core metro markets and deeper penetration in Tier 3 and Tier 4 cities/ towns.
  - Swasthfit contributed 27% in Q1 FY26
- **EBITDA increased by 13.1% Y-o-Y in Q1 FY26**
  - Driven by sustained volume growth, network expansion and favorable mix combined with the efficient hub-and-spoke model and technology to achieve economies of scale and cost efficiencies






# Operating highlights


## No. of Clinical Laboratories




## No. of PSCs




## No. of PUPs






## No. of Patients (Mn)



## No. of Samples (Mn)



# Robust financial performance




- Growth driven primarily by increasing patient volumes and realization
- Increase in operating margin due to economies of scale and cost efficiencies

EBITDA Margin	24.3%	27.4%	28.3%
PAT Margin	12.0%	16.3%	20.0%
ROCE	24%	35%	48%

# Robust financial performance (Cont'd)


Times

## Fixed Asset Turnover<sup>1</sup>



(INR Cr.)

## Cash and Cash Equivalents



- Self funded growth on account of strong cash flow generation
- Attractive fixed asset turnover ratio given asset-light model
- Current net cash position and internal accruals expected to fund next phase of growth

1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS

# Management Commentary



**(Hony.) Brig. Dr. Arvind Lal,  
Padma Shri  
Executive Chairman**

**Commenting on the performance, (Hony.) Brig. Dr. Arvind Lal, Executive Chairman said:**

*"India's healthcare landscape is transforming rapidly, driven by the twin engines of digital innovation and increasing healthcare infrastructure. However, significant gaps remain, whether it is the rising burden of chronic diseases and lifestyle disorders, or the challenge of timely diagnostics in underserved geographies. These structural realities underline the essential role of accessible, high-quality diagnostics in improving health outcomes nationwide.*

*At Dr. Lal PathLabs, we are scaling responsibly to meet this need by deepening our advanced test portfolio as well as expanding our presence in Tier-3 & below markets.*

*Technology continues to be a cornerstone of our strategy. From AI-integrated lab systems to user-centric digital platforms, our investments are focused on driving both operational efficiency and enhanced patient experience. With a scalable model and a clear sense of purpose, we are confident in our ability to serve the evolving needs of Indian healthcare with precision, trust, and care."*



**Mr. Shankha Banerjee,  
Chief Executive Officer**

**Commenting on the performance, Mr. Shankha Banerjee, Chief Executive Officer said:**

*"Our first-quarter performance reinforces the strength of our business model and disciplined execution. We are expanding access to high-quality diagnostics through a calibrated network rollout, deeper reach in core metro markets and increased presence in underpenetrated regions. The diagnostics landscape continues to evolve, and we are positioning ourselves to lead not just in scale, but also in trust and reliability.*

*We are steadily broadening our capabilities across advanced diagnostics, including genomics, auto-immunity and other high-complexity testing, to ensure that our offerings meet both emerging and unmet needs in healthcare. Our SwasthFit program continues to gain momentum, helping us deliver diagnostic solutions that support clinical decision-making and aid prevention. We continue to invest in Technology, which remains central to how we operate and grow.*

*Our outlook is shaped by a relentless focus on volume-led growth through market expansion, focus on operational excellence via digital transformation and sustaining our brand leadership through quality and accessibility."*



**Mr. Ved Prakash Goel,  
Group CFO & CEO –  
International Business**

**Commenting on the performance, Mr. Ved Prakash Goel, Group CFO & CEO – International Business said:**

*"We have commenced FY26 on a strong note, with steady growth in volumes and healthy improvement in business mix, yielding a robust financial outcome. By prioritizing execution excellence and cost discipline, we have successfully sustained profitability while maintaining strategic flexibility for future investments.*

*During the quarter, we further deepened our presence across underserved markets, bolstered by the new labs and PSCs rolled out last year. This tiered expansion strategy is helping us unlock new demand pockets while fortifying our leadership in core regions. The integration of Suburban Diagnostics with Dr Lal PathLabs is started contributing to our performance momentum in West India.*

*Looking to the future, we remain focused on investing in technology-led efficiencies and scaling our presence across key geographies. With a robust balance sheet and a clearly defined growth roadmap, we are confident of delivering sustainable long-term value."*

# Corporate Overview

# Overview of Dr. Lal PathLabs



## Established brand

Established consumer healthcare brand in diagnostic services



## Pan-India integrated coverage

298 clinical labs (including National Reference Lab at Delhi and Regional Reference labs at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs)



## Varied Offerings

Catalogue of 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests



## Unique and successful operating model

Scalable model integrated through centralized IT platform allows for network expansion

**Well-positioned in one of the fastest-growing segments of the Indian healthcare industry.**

# Our Evolution

- **1949:** Founded by Dr. Major S. K. Lal
- **1995:** Company incorporated as Dr. Lal PathLabs Private Ltd.
- **2000:** Three clinical labs receive NABL<sup>1</sup> accreditation
- **2001:** Received ISO 9001:2008 certification
- **2002:** Received 'International Accreditation' from CAP<sup>2</sup>

**1949-2005**

## Foundation

### Building capabilities for scale up

- **2005:** onwards: Investment by WestBridge Capital
- **2008:** Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited
- **2010:** National Reference Lab set up in Delhi

**2005-2010**

- Investment by TA Associates
- Clinical laboratories expansion in North region
- Growing the business in East region
- Entry into the South and West regions
- Multiple acquisitions to scale network
- Successful IPO listing in Dec 2015

**2010-2015**

### Strong position in North India, building network in other geographies

### Higher contribution from Rest of India, Commissioned state of the art Kolkata Reference Lab

- Higher contribution from Rest of India business & focus on bundled test program "Swasthfit"
- Successful commissioning of Regional Reference Lab at Kolkata in 2018
- Inorganic growth through acquisition of laboratories in Western & Southern India

**2015-2020**

**2020 onwards**


- First to set-up RT-PCR testing network in 2020
- Completed acquisition of Suburban Diagnostics in 2021
- Expanded South ecosystem through Bengaluru Reference Lab and network of Hub & Satellite labs
- Established hub labs in North region
- Spearheading investments in Digital and InfoSec
- Successful commissioning of Regional Reference Lab at Mumbai in 2023

### Pan India Player – Acquired Suburban, Building South Ecosystem

1. NABL: National Accreditation Board for Calibration and Testing Laboratories.  
2. CAP: College of American Pathologists.



# Most trusted healthcare brand in Diagnostic Services



## Pillar of a Strong Brand

- Accreditations from CAP, NABL and ISO
- Centrally administered surveillance programs
- Coverage in metros, Tier 1, Tier 2 & Tier 3+ cities
- Wide reach through PSCs and PUPs
- 24x7 access including online access and home collection
- Dedicated logistics team

Accreditations



Nationwide Network



Digital capabilities




Fast Turnaround Time



# Collection network

LPL's scalable business model provides strategic advantage for expansion and consolidation



*Single brand pulls patients*

*Walk-in customers account for highest share of revenues*

*Diverse, large customer pool offers monetization opportunities*

# Digital Touchpoints across patient journey

- Patient App/Website – Order Booking, Reports, Find Nearby Center, Test Info, Expected time of report, Live order status, App Notifications
- Partner Portal – Registration, Business snapshots, Report Download, AI enabled Recommendation engine
- Home Collection Portal – Customer Order Booking, Report status
- Seamless Omni channel Experience

## DIGITAL POINT OF SALE APPLICATIONS



## SAMPLE COLLECTION

- Phlebo App – Scan lab number, Documentation, Order Closures for home collection
- Phlebo Kiosk – In lab application for Phlebo
- Customer Feedback/NPS Scoring



- Live tracking of samples, inter & intra city, cash collection, dynamic routing, gamification, lab shipments
- Audit

## LOGISTICS



## LAB PROCESSING

- Reporting & Analysis
- Instruments integrations
- Quality & Compliance
- Workflow Management



- Historical Trends
- Cumulative Reporting
- Smart Report
- RPA For Govt. Reporting
- Live Report Status/ETR
- ABDM – DLPL amongst the early adopters

## REPORT ENGINE



Customers

DATA LAKE – REAL  
TIME ANALYTICS

MICROSERVICES  
BASED  
ARCHITECTURE


SECURED  
APPLICATIONS

SCALABLE INFRA –  
LEVERAGING POWER  
OF CLOUD


# ABDM - All Milestones achieved, DLPL among early adopters

**Ayushman Bharat Digital Mission** aims to create a National Digital Health Ecosystem to bridge the existing gap amongst different stakeholders of Healthcare ecosystem through digital highways. The mission also enables interoperability and portability of health records and support innovation and research in the health sector.

## The NDHM ECOSYSTEM



The program is divided into 3 milestones from Technology enablement perspective.



Integrated: M1, M2, M3

**DLPL IS AMONG THE FEW EARLY ADOPTERS WHO HAVE RECEIVED ALL M1, M2 AND M3 CERTIFICATION.**

The benefits of the mission are manifold and will help the entire ecosystem, from Policy Makers to Researchers, and Health Care Professionals to Patients.

# Vision, Mission & Values

## VISION

Be the most  
trusted healthcare  
partner, enabling  
healthier lives



## MISSION

To be an undisputed  
market leader by providing  
accessible, affordable,  
timely and quality  
healthcare, diagnostics,  
applying insights and  
cutting-edge technology to  
create value for all  
stakeholders



## VALUES

Customer First  
Ethics & Integrity  
Quality  
Accountability  
Empathy & Compassion



# DLPL Strategy for future growth

**Drive increased volume in high-potential West & South India; Hub labs in North**



- Follow cluster city approach
- Enhance presence in Maharashtra especially Mumbai
- Launched Reference labs in Bengaluru & Mumbai

**Enhance high-end test portfolio of super-specialty & bundled test**



- Established specialty verticals: Genevolve (genomics), L-CoRD (reproductive diagnostics), L-ACE (auto-immune disorders)
- Swasthfit: Core for comprehensive patient solutions.

**Significantly leverage the strong digital infrastructure**



- AI/ ML-powered data analytics for enhanced patient experience & personalized solutions.
- Dedicated digital team driving volume growth

**Maintain leadership position in the existing core markets**



- Leverage strong brand equity in core market of North India
- Offer value to patients by up-selling opportunities

# Leveraging digital infrastructure to make life easier for patients



## New Website Launch

- New age user intuitive website.
- Responsive , mobile friendly web designs.
- SEO friendly for improved customer reach
- Strategic placement of Buttons and Web forms to generate more leads and better order conversion rates from website



## Reco.ai

- LPL's own AI based Recommendation Engine
- Recommends Patient relevant tests as per his current health condition, past report trends, demographic details, etc.



## Logistics App

- Machine Learning based FE Route Generation
- Machine Learning based Tube Scanning Bag creation process.
- Secure QR Code based handshake for every process.
- Geo-fencing and Precious sample recognition Intra and Intercity sample movement.



## Wallet

- Senior Citizen Wallet: Wallet points on every booking for Senior Citizen Patients.
- Phlebo Wallet: Wallet points on enhanced superior services to customers.



## One Registration


- One unified platform for all POS registrations
- Error Proofing



## Chatbot 2.0

- New version of Chatbot.
- Book an appointment functionality.
- ETR and Report visibility of customer orders. Recommendation of Preventive Health Checkups





# First in South Asia - Amyloid Typing


## Amyloid Protein Typing Facility





**Dr. Lal PathLabs becomes south Asia's first diagnostic chain to offer advance test for amyloidosis: a rare, life-threatening protein disorder**

In a significant medical advancement, Dr. Lal PathLabs has launched South Asia's first advanced test for amyloidosis, a rare protein disorder. The test, guided by the National Amyloidosis Centre, uses cutting-edge technology to determine amyloid subtypes, enabling precise and targeted treatment.

### Amyloid Typing by Laser Microdissection & Mass Spectrometry



11	0.41 K1C16_HUMAN	549	51578	51	30	24	15 K1C16_HUMAN
6	0.3 K1C14_HUMAN	489	51872	41	26	19	12 K1C14_HUMAN
25	0.5 APOA4_HUMAN	697	45344	65	39	25	18 APOA4_HUMAN
23	0.64 APOE_HUMAN	646	36246	56	40	23	18 APOE_HUMAN
3	0.31 IGGC_HUMAN	342	11929	13	8	3	2 IGGC_HUMAN
7	0.17 VTNC_HUMAN	263	55069	23	14	7	6 VTNC_HUMAN
6	0.41 HBB_HUMAN	257	16102	18	9	6	3 HBB_HUMAN
3	0.26 ACTB_HUMAN	238	42052	25	12	11	6 ACTB_HUMAN
3	0.25 ACTA_HUMAN	162	42381	25	12	11	6 ACTA_HUMAN
7	0.31 SAMP_HUMAN	166	29485	12	8	7	4 SAMP_HUMAN
5	0.03 LAMC1_HUMAN	130	183191	9	6	5	3 LAMC1_HUMAN
6	0.14 CLUS_HUMAN	111	53031	14	4	6	3 CLUS_HUMAN



**Under the Guidance of the National Amyloidosis Centre, London (UK)**

# Highest Quality Standards in the Industry



**Best in the Industry CAP Proficiency Testing Score at 98.0% for National Reference Lab**

**Consistently high EQAS Performance Testing Score at 98.3% for Satellite Labs**


**CAP accreditation 2 labs, NABL accreditation 40 Labs**

**Real time  
quality control  
monitoring**

**Risk based  
quality  
assurance  
framework**

**100+ Quality  
improvement  
meetings on a  
daily basis  
with the  
network  
partners**


**Digitally  
enabled  
solutions  
implemented  
for quality  
audits and  
trainings**




**Patent has been granted to Dr. Lal PathLabs for an invention related to REAL TIME QUALITY CONTROL MONITORING for the period of 20 years**



## Laboratory excellence



## Capability building



# Control Tower Implementation

**“Control Tower” implementation provides a complete visibility of Patient samples across the sample processing lifecycle. The insights will help the business users to reduce delay and improve processing leading to better customer service.**

## Control Tower Teams



### Front Desk

**Failure Indicator Areas** - Home Collection, Credit management & Sample/Registration Deficiency



### Logistics

**Failure Indicator Areas** - Unregistered Samples, Bagging & Shipping of samples



### Lab Operations

**Failure Indicator Areas** - samples scan-in & scan-out, Shipment creation, Report Validation



### Digital

**Failure Indicator Areas:** Delay in report upload and payment

## Key Highlights

- Centralized Monitoring Team for **“Control Tower”** Operation
- Real-time information for the delays happening across sample processing lifecycle with actionable insights
- Quick decision making
- Drill-down level information available till last leaf i.e. Lab Number / Field Executive
- Information accessible based on Roles & Rights
- Overall design is based on **“Mobile First”** Approach

## D365 Cloud Data Lake


- Future ready Cloud architecture with easily scalable and upgradable
- Cloud ERP Microsoft Dynamics 365 for Finance & Operations
- Data for **“Control Tower”** is processed through **“Data Lake”** hosted on Cloud
- **“Data Lake”** helps in consolidating the data from multiple source systems and provides easy access information securely

# Enhanced Customer Experience in Home Collection



# Key ESG Initiatives

Commissioned 3.18 MW Solar System for generating the green energy



Use of Electric bikes for sample collection

Saved 16,43,858 Kg of CO2 emissions by using Solar power

Use of biodegradable bags for sample collection

Installed R32 refrigerant operated Inverter AC for Conserving ozone layer


All labs are equipped with Effluent Treatment Plant for wastewater treatment

49,384 hours of training for employee development

Descaling of DG Sets radiator to improve the smoke quality



# Cyber Security Capability



# Experienced Management team

**(Hony.) Brig.  
Dr. Arvind Lal  
Padma Shri**

**Executive  
Chairman**



**Dr. Vandana Lal**

**Whole-time  
Director**



**Shankha  
Banerjee**

**Chief Executive  
Officer**



**Ved Prakash  
Goel**

**Group CFO &  
CEO –  
International  
Business**



**Munender  
Soperna**

**Group Chief  
Information &  
Digital  
Officer**



**Jai Prakash  
Meena**

**Chief  
Operating  
Officer**



**Manoj Garg**


**Group Chief  
Human  
Resources  
Officer**





## Investment Highlights

# Investment Highlights



# Indian Healthcare Services is a large and growing opportunity

**~1.51 bn**

India's expected population in 2030<sup>1</sup>

**Rs. 16.5-17.5 trillion**

Expected India's healthcare industry size in FY 28<sup>2</sup>

**\$10.76 bn**

Close to Rs. 89,155 crore was allocated to the Ministry of Health and Family Welfare, under Union Budget 2023-24<sup>6</sup>

**2.5%**

Government Expenditure on healthcare (as % of GDP) in FY25<sup>5</sup>

**~50.6%**


Out of pocket expenses to overall healthcare spends<sup>3</sup>

**\$6.8 bn**

The amount that Indian Government is planning to introduce as a credit incentive program (Rs. 500 bn) to boost the country's healthcare infrastructure<sup>6</sup>


Per capita current expenditure on health in \$ terms (2020)<sup>4</sup>

**Globally: Total Healthcare Expenditure is 10.9% of GDP**




# Drivers of India diagnostic services market

## Diagnostic Services Industry Size




**Screening, early detection, and monitoring reduce downstream costs**

## Growth Drivers




# Diagnostic Services industry continues to remain highly fragmented

## Highly Fragmented Industry




***Largely fragmented and unorganized***

## Region wise Revenue



***Diagnostic penetration in rural market is lower, while the opportunity size remains big***

## Shareholding as of 30th June, 2025



\*Mutual Funds includes Alternate Investment Funds as well



# Key Awards & Recognition



Top 100 Global Most Loved Workplace 2023



Gold Award  
QCI – D. L. Shah Quality Awards - 2022



Business Standard Star  
SME of the year 2022



Best Brands Healthcare  
2022



GAPIO Excellence in  
Diagnostics Award 2022



Diagnostic Chain of the  
Year – West  
Awarded by the  
prestigious Healthcare  
Awards, from The  
Economic Times in 2022



CSR Award 2022



ICICI Lombard & CNBC  
TV18 India Risk  
Management Awards  
2022 – Healthcare



CFO100 Roll of Honour  
2022



Financial Express CFO of  
the year 2022



Dr. Om Manchanda  
honoured and awarded as  
'Healthcare Personality of  
the Year, 2020' by FICCI



EY Entrepreneur of The  
Year 2019 – Life  
Sciences & Healthcare



Data Quest Technology  
Award 2015 – Excellence  
in Implementation of  
Technology



VC Circle Healthcare  
Summit 2013 – Best  
Diagnostic Company



Computerworld Honors  
Laureate Program, 2012



Frost and Sullivan 4th  
Annual India Healthcare  
Excellence Award,  
'Diagnostic Service  
Provider Company of the  
Year 2012'



Franchise India  
Excellence Award in Hall  
of Fame Category (2011,  
2012)



Franchisor of the Year  
(Healthcare) - Franchise  
Plus Awards 2010



Padma Shri – (Hony)  
Brig. Dr. Arvind Lal  
(2009)

## About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests as on March 31, 2025.

As on March 31, 2025, DLPL's has 298 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). In FY25 & FY24, DLPL collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.

**Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388**

**Website:** <https://www.lalpathlabs.com>

## For further information please contact:

**Ved Prakash Goel**

**Dr. Lal PathLabs Limited**

Tel: +91 124 301 6500

Fax: +91 124 423 4468

E-mail: [ved.goel@lalpathlabs.com](mailto:ved.goel@lalpathlabs.com)

---

**Siddharth Rangnekar / Nishid Solanki**

**CDR India**

Tel: +91 22 66451209 / 1221

Fax: +91 22 66451213

Email: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com) / [nishid@cdr-india.com](mailto:nishid@cdr-india.com)